Uniphar plc, the Dublin-headquartered international diversified healthcare services business, has announced a series of board-level changes effective November and January 2027. Roger Gillespie, a Chartered Accountant and former KPMG partner, will join the board as an independent non-executive Director from 25 January 2027. Separately, Paul Hogan assumed the role of Chair on 18 November 2026, succeeding Maurice Pratt, who steps down from that position after 17 years but remains on the board until 6 May 2027. The changes signal a generational shift at the top of a company that serves more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions.

Key Points

  • Uniphar plc (UPR), an international diversified healthcare services group headquartered in Dublin, Ireland
  • Roger Gillespie appointed as independent non-executive Director with effect from 25 January 2027; Paul Hogan became Chair on 18 November 2026
  • Gillespie holds 86,957 ordinary shares in the company and no options; Maurice Pratt remains on the board until 6 May 2027
  • Investors should watch how the refreshed board steers Uniphar's expansion across Europe, North America, APAC and MENA

Roger Gillespie Brings Four Decades of KPMG Experience to Uniphar Board

Roger William Gillespie, an Irish citizen aged 66, joins Uniphar as an independent non-executive Director on 25 January 2027. A Chartered Accountant, he spent over four decades at KPMG, serving as both Audit Partner and Deal Advisory Partner for some of Ireland's largest publicly listed and private companies across the healthcare, industrial, retail and agri-food sectors. Since retiring from KPMG in 2024, Gillespie has taken on consultancy work and several non-executive board roles, including in the healthcare sector. The company states he brings expertise in financial reporting, corporate governance, equity capital and debt markets, and mergers and acquisitions. He holds 86,957 ordinary shares and no options in Uniphar.

Paul Hogan Assumes Chair Role as Maurice Pratt Ends 17-Year Tenure Leading the Board

Maurice Pratt stepped down as Chair of Uniphar on 18 November 2026, with Paul Hogan taking over the role on the same date. Pratt, who served on the Uniphar board for over 20 years, including 17 years as Chair, will remain as a Director until 6 May 2027. Chief Executive Officer Ger Rabbette credited Pratt with steering Uniphar through the aftermath of the 2008 financial crisis, overseeing the acquisition of CMR, expanding the business beyond Ireland into Europe and the United States, and guiding the company to its 2019 stock market flotation. Sue Webb also assumed the role of Senior Independent Director on 18 November 2026, replacing Paul Hogan in that capacity.

Uniphar's Three-Division Model and Global Reach Provide the Strategic Context for Governance Refresh

Uniphar operates across three divisions — Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail — serving manufacturers across Europe, North America, APAC and MENA, with product delivery to more than 160 countries. The Supply Chain & Retail arm is Ireland's leading pharmaceutical wholesaler; Medtech is a pan-European medical device distributor; and Pharma operates globally, supporting manufacturers in bringing innovative medicines to market. The board appointments come as the group pursues continued international expansion. Investors may be watching whether Gillespie's mergers and acquisitions experience at KPMG supports that growth agenda under a refreshed governance structure.